Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRONCHIPHARMA Study
2023-510220-72-00Phase 4Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bronchiectasis and chronic bronchitis (CB) comparing Inhaled tobramycin, Inhaled colistimethate sodium and Placebo (0.9% sodium chloride solution) (3 arms). Primary endpoint: Number of colony forming units (CFU). Planned start Jun 2024; status: authorised.
02
Drugs
tobramycincolistimethate sodium
03
Conditions
bronchiectasischronic bronchitis (CB)
Beyond the preview
Go deeper on 2023-510220-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510220-72-00.